Thu, Nov 21, 2024
[Archive]
Volume 32, Issue 152 (May & June 2024)
J Adv Med Biomed Res 2024, 32(152): 174-184 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahrami A, Nikoomanesh F, Dehghani H, Aramjoo H, A. Ferns G. Curcumin Ameliorates Depression, and Anxiety in Patients with Premenstrual Syndrome and Dysmenorrhea: A Triple-Blinded Placebo-Controlled Trial. J Adv Med Biomed Res 2024; 32 (152) :174-184
URL: http://journal.zums.ac.ir/article-1-7456-en.html
URL: http://journal.zums.ac.ir/article-1-7456-en.html
1- Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine , bahramiaf@mums.ac.ir
2- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
3- Infectious Diseases Research Center,
4- Student Research Committee, Birjand University of Medical Sciences
5- Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK
2- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
3- Infectious Diseases Research Center,
4- Student Research Committee, Birjand University of Medical Sciences
5- Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK
Abstract: (151 Views)
Background & Objective: Premenstrual syndrome (PMS) and primary dysmenorrhea (PD) are gynecological conditions that are associated with psychological and mood disorders. This study assessed the effects of curcumin, a natural polyphenol, on depression, anxiety, stress and quality of life (QL) in woman with PMS and PD.
Materials & Methods: The study was undertaken in 128 women who were randomised to treatment with either curcumin (n=64) or placebo (n=64) groups. Each subject received one capsules (500 mg of curcuminoids plus 5 mg piperine, or a placebo, plus 5 mg piperine) daily, for 3 successive menstrual cycles. Psychological status and QL were assessed using Depression, Anxiety, Stress Scales-21 (DASS-21) and the Short Form-12 (SF-12) questionnaires respectively.
Results: Overall scores as well as the mental health domain of the SF-12 improved significantly after curcumin supplementation (P<0.05). In addition, curcumin decreased significantly (P<0.05) all of the DASS-21 domains (depression, anxiety and stress). Significant differences were also found between the two groups for the DASS-21 domains, SF-12 mental health (total) and overall scores (P<0.05).
Conclusion: Curcuminoids may be useful as a natural, widely accessible therapeutic option for the management of the psychological impact of PMS and PD, and improve the QL of women with these conditions.
Materials & Methods: The study was undertaken in 128 women who were randomised to treatment with either curcumin (n=64) or placebo (n=64) groups. Each subject received one capsules (500 mg of curcuminoids plus 5 mg piperine, or a placebo, plus 5 mg piperine) daily, for 3 successive menstrual cycles. Psychological status and QL were assessed using Depression, Anxiety, Stress Scales-21 (DASS-21) and the Short Form-12 (SF-12) questionnaires respectively.
Results: Overall scores as well as the mental health domain of the SF-12 improved significantly after curcumin supplementation (P<0.05). In addition, curcumin decreased significantly (P<0.05) all of the DASS-21 domains (depression, anxiety and stress). Significant differences were also found between the two groups for the DASS-21 domains, SF-12 mental health (total) and overall scores (P<0.05).
Conclusion: Curcuminoids may be useful as a natural, widely accessible therapeutic option for the management of the psychological impact of PMS and PD, and improve the QL of women with these conditions.
Type of Study: Original Article |
Subject:
Clinical medicine
Received: 2024/03/12 | Accepted: 2024/08/18 | Published: 2024/06/21
Received: 2024/03/12 | Accepted: 2024/08/18 | Published: 2024/06/21
References
1. Bahrami A, Ariakia F, A Ferns G, Ghayour-Mobarhan M. The prevalence of menstrual problems amongst adolescent girls in Northeastern Iran. J Adv Med Biomed Res. 2022;30(138):61-8. [DOI:10.30699/jambs.30.e55702]
2. Elazar AB, Canetti L, Azoulay M, Dan R, Goelman G, Segman R, et al. Quality of life among university students with premenstrual symptoms: The role of emotion regulation. Europ Psychiatr. 2023;66(S1):S648-S9.
3. Adib-Rad H, Kheirkha F, Faramarzi M, Omidvar S, Basirat Z, Ahmadi MH. Primary dysmenorrhea associated with psychological distress in medical sciences students in the north of Iran: a cross-sectional study. Int J Fertil Steril. 2022;16(3):224
4. Kahal F, Alshayeb S, Torbey A, Al Helwani O, Kadri S, Al Helwani A, et al. The prevalence of menstrual disorders and their association with psychological stress in Syrian students enrolled at health-related schools: A cross-sectional study. Int J Gynaecol Obstet. 2024;164(3):1086-1093 [DOI:10.1002/ijgo.15152]
5. Charlton A, While D. Smoking and menstrual problems in 16-year-olds. J Royal Soc Med. 1996;89(4):193-5. [DOI:10.1177/014107689608900405]
6. Weyand AC, Fitzgerald KD, McGrath M, Gupta V, Braun TM, Quint EH, et al. Depression in female adolescents with heavy menstrual bleeding. J Pediatr. 2022;240:171-6. [DOI:10.1016/j.jpeds.2021.09.007]
7. da Silva MFO, de Azevedo LO, Campelo MGdOC, Wanderley NC, Sobral MKM, de Albuquerque GPM. Premenstrual syndrome: possibilities of care for symptom attenuation. Rev Med (São Paulo). 2023;102(3):196886. [DOI:10.11606/issn.1679-9836.v102i3e-196886]
8. Shahbazi F, Eslampanah Z, Niaparast M. Prevalence of symptoms and medication use among female medical students and pharmacy clients with premenstrual syndrome: a cross‐sectional study in Iran. J Pharm Pract Res. 2020;50(1):55-60. [DOI:10.1002/jppr.1609]
9. Sarahroodi S, Maleki-Jamshid A, Sawalha AF, Mikaili P, Safaeian L. Pattern of self-medication with analgesics among Iranian University students in central Iran. J Family & Communit Med. 2012;19(2):125. [DOI:10.4103/2230-8229.98302]
10. Hong J, Bose M, Ju J, Ryu J-H, Chen X, Sang S, et al. Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A 2, cyclooxygenases and 5-lipoxygenase. Carcinogen. 2004;25(9):1671-9. [DOI:10.1093/carcin/bgh165]
11. Moriyuki K, Sekiguchi F, Matsubara K, Nishikawa H, Kawabata A. Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κB in human lung epithelial cells. J Pharmacol Sci. 2010;114(2):225-9. [DOI:10.1254/jphs.10126SC]
12. Mythri R, M Srinivas Bharath M. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr Pharm Design. 2012;18(1):91-9. [DOI:10.2174/138161212798918995]
13. Xu Y, Ku B-S, Yao H-Y, Lin Y-H, Ma X, Zhang Y-H, et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav. 2005;82(1):200-6. [DOI:10.1016/j.pbb.2005.08.009]
14. Bahrami A, Zarban A, Rezapour H, Agha Amini Fashami A, Ferns GA. Effects of curcumin on menstrual pattern, premenstrual syndrome, and dysmenorrhea: A triple‐blind, placebo‐controlled clinical trial. Phytother Res. 2021;35(12):6954-62. [DOI:10.1002/ptr.7314]
15. Khayat S, Fanaei H, Kheirkhah M, Moghadam ZB, Kasaeian A, Javadimehr M. Curcumin attenuates severity of premenstrual syndrome symptoms: A randomized, double-blind, placebo-controlled trial. Complement Ther Med. 2015;23(3):318-24. [DOI:10.1016/j.ctim.2015.04.001]
16. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Molec Pharmaceut. 2007;4(6):807-18. [DOI:10.1021/mp700113r]
17. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendía LE, Majeed M, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016;82:578-82. [DOI:10.1016/j.biopha.2016.05.037]
18. Crichton N. Visual analogue scale (VAS). J Clin Nurs. 2001;10(5):706-6.
19. Siahbazi S, Hariri FZ, Montazeri A, Banaem LM. Translation and psychometric properties of the Iranian version of the Premenstrual Symptoms Screening Tool (PSST). Payesh (Health Monitor). 2011;10(4):421-7.
20. Sahebi A, Asghari M, Salari R. Validation of depression anxiety and stress scale (DASS-1) for an Iranian population. J Develop Psychol. 2005;1(4):36-54.
21. Montazeri A, Vahdaninia M, Mousavi SJ, Omidvari S. The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity. BMC Public Health. 2009;9(1):1-10. [DOI:10.1186/1471-2458-9-341]
22. Martin MO, Mullis IV, Kennedy AM. Progress in International Reading Literacy Study (PIRLS): PIRLS 2006 Technical Report. Int Assoc Evaluat Educat Achiev. 2007.
23. Ahmadnezhad M, Asadi Z, Miri HH, Ebrahimi-Mamaghani M, Ghayour-Mobarhan M, Ferns GA. Validation of a short semi-quantitative food frequency questionnaire for adults: a pilot study. J Nutr Sci Dietetics. 2017:49-55.
24. Farrokh-Eslamlou H, Oshnouei S, Heshmatian B, Akbari E. Premenstrual syndrome and quality of life in Iranian medical students. Sex Reprod Healthc. 2015;6(1):23-7. [DOI:10.1016/j.srhc.2014.06.009]
25. McGovern CE, Cheung C. Yoga and quality of life in women with primary dysmenorrhea: a systematic review. J Midwife Women's Health. 2018;63(4):470-82. [DOI:10.1111/jmwh.12729]
26. Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, et al. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr. 2020;60(15):2643-53. [DOI:10.1080/10408398.2019.1653260]
27. Al‐Karawi D, Al Mamoori DA, Tayyar Y. The role of curcumin administration in patients with major depressive disorder: mini meta‐analysis of clinical trials. Phytother Res. 2016;30(2):175-83. [DOI:10.1002/ptr.5524]
28. Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: a meta-analysis. J Am Med Direct Assoc. 2017;18(6):503-8. [DOI:10.1016/j.jamda.2016.12.071]
29. Lamers F, Milaneschi Y, De Jonge P, Giltay E, Penninx B. Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychol Med. 2018;48(7):1102. [DOI:10.1017/S0033291717002483]
30. Arbabi M, Shirmohammadi M, Taghizadeh Z, Mehran A. The effect of premenstrual syndrome on quality of life in adolescent girls. Iran J Psychiatr. 2008:105-9.
31. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14(7):1693-703. [DOI:10.1007/s11136-005-2816-9]
32. Iacovides S, Avidon I, Bentley A, Baker FC. Reduced quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta obstetricia et gynecologica Scandinavica. 2014;93(2):213-7. [DOI:10.1111/aogs.12287]
33. Kaufmann FN, Gazal M, Bastos CR, Kaster MP, Ghisleni G. Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Europ J Pharmacol. 2016;784:192-8. [DOI:10.1016/j.ejphar.2016.05.026]
34. Sarraf P, Parohan M, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Short-term curcumin supplementation enhances serum brain-derived neurotrophic factor in adult men and women: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Res. 2019;69:1-8. [DOI:10.1016/j.nutres.2019.05.001]
35. Sahebkar A, Serban M-C, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Function Foods. 2015;18:898-909. [DOI:10.1016/j.jff.2015.01.005]
36. Gilhotra N, Dhingra D. GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain Res. 2010;1352:167-75. [DOI:10.1016/j.brainres.2010.07.007]
37. Di Ciaula A, Portincasa P, Maes N, Albert A. Efficacy of bio-optimized extracts of turmeric and essential fennel oil on the quality of life in patients with irritable bowel syndrome. Ann Gastroenterol. 2018;31(6):685. [DOI:10.20524/aog.2018.0304]
38. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability‐boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double‐blind placebo‐controlled trial. Phytother Res. 2014;28(10):1461-7. [DOI:10.1002/ptr.5149]
39. Sadeghian M, Rahmani S, Jamialahmadi T, Johnston TP, Sahebkar A. The effect of oral curcumin supplementation on health-related quality of life: A systematic review and meta-analysis of randomized controlled trials. J Affect Disorder. 2020. [DOI:10.1016/j.jad.2020.09.091]
40. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64:353-6. [DOI:10.1055/s-2006-957450]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
